SPECIAL
LECTURES
SPECIAL LECTURES: SPEAKERS
The IUIS 2025 Congress in Vienna will feature Special Lectures by distinguished Nobel laureates, highlighting groundbreaking advancements in immunology and related fields. Among the esteemed speakers are:
James P. Allison: An American immunologist renowned for his pioneering work in cancer immunotherapy. His research on T-cell development and activation led to the development of novel cancer treatments, earning him the Nobel Prize in Physiology or Medicine in 2018.
Emmanuelle Charpentier: A French microbiologist and geneticist awarded the Nobel Prize in Chemistry in 2020 for co-developing the CRISPR-Cas genome editing technology. Her work has revolutionized life sciences research, opening new possibilities in biotechnology and gene therapies.
These lectures offer attendees a unique opportunity to gain insights from leading scientists whose discoveries have significantly impacted health and disease understanding.
Biography
James Patrick Allison is an American immunologist and Nobel laureate who holds the position of professor and chair of immunology and executive director of immunotherapy platform at the MD Anderson Cancer Center at the University of Texas. His discoveries have led to new cancer treatments for the deadliest cancers. He is also the director of the Cancer Research Institute (CRI) scientific advisory council. He has a longstanding interest in mechanisms of T-cell development and activation, the development of novel strategies for tumor immunotherapy, and is recognized as one of the first people to isolate the T-cell antigen receptor complex protein. In 2014, he was awarded the Breakthrough Prize in Life Sciences; in 2018, he shared the Nobel Prize in Physiology or Medicine with Tasuku Honjo. The scientists’ groundbreaking work on the immune system has paved the way for a new class of cancer drugs that are already dramatically changing outcomes for patients.
Biography
Emmanuelle Charpentier was awarded the Nobel Prize in Chemistry in 2020 for her joint work with Jennifer Doudna onthe development of a method for genome editing. This technology, known as CRISPR-Cas, is revolutionizing research in the life sciences. CRISPR-Cas has opened entirely new possibilities in biotechnology and biomedical gene therapies that have an impact on society and humanity. Charpentier is Scientific and Managing Director at the Max Planck Unit for the Science of Pathogens in Berlin. Charpentier has devoted most of her scientific career to understanding the fundamental mechanisms of diseases, with a particular interest in infections caused by Gram-positive pathogenic bacteria such as Listeria, staphylococci and streptococci.